Yahoo · Nov 9, 2026
Mizuho names its top SMID biotech pick for November
Investing.com -- Mizuho Securities has selected its top pick in the small- and midcap biotechnology sector for November, maintaining an Outperform rating.
RG
NASDAQ · RGNX
REGENXBIO Inc.
Healthcare · Biotechnology
$8.03
Down-$0.44 (-5.19%)
Updated Nov 13, 2026, 1:00 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 650.96M
- P/E ratio
- -3.74
- Dividend yield
- 0.00%
- 52-week range
- $5.46 – $15.88
- Volume
- 1.29M
- Avg. volume
- 586.76K
Price performance · RGNX
RGNX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 12, 2026
RGNX closed at $8.03 after 21 trading sessions, up 12.15% for the selected period.
- Last close
- $8.03
- Period change
- +12.15%
- Period low
- $6.58
- Period high
- $8.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | $8.23 | $8.33 | $7.94 | $8.03 | 1.29M |
| Nov 11, 2026 | $7.80 | $8.88 | $7.62 | $8.47 | 1.85M |
| Nov 10, 2026 | $8.00 | $8.14 | $7.28 | $7.69 | 1.08M |
| Nov 9, 2026 | $7.77 | $8.23 | $7.47 | $8.07 | 2.17M |
| Nov 6, 2026 | $7.33 | $7.87 | $7.33 | $7.62 | 1.19M |
| Nov 5, 2026 | $7.20 | $7.68 | $7.15 | $7.38 | 1.68M |
| Nov 4, 2026 | $7.72 | $7.96 | $7.475 | $7.71 | 1.31M |
| Nov 3, 2026 | $7.29 | $7.645 | $7.266 | $7.63 | 854.96K |
| Nov 2, 2026 | $7.27 | $7.4586 | $7.04 | $7.16 | 1.03M |
| Oct 30, 2026 | $7.38 | $7.535 | $7.00 | $7.20 | 1.06M |
| Oct 29, 2026 | $7.36 | $7.63 | $7.21 | $7.41 | 1.04M |
| Oct 28, 2026 | $6.52 | $7.285 | $6.505 | $7.24 | 2M |
| Oct 27, 2026 | $6.54 | $6.78 | $6.4586 | $6.60 | 1.22M |
| Oct 26, 2026 | $6.74 | $6.89 | $6.48 | $6.58 | 1.14M |
| Oct 23, 2026 | $7.03 | $7.08 | $6.6284 | $6.68 | 1.45M |
| Oct 22, 2026 | $7.11 | $7.305 | $6.98 | $7.17 | 1.13M |
| Oct 21, 2026 | $7.42 | $7.47 | $7.15 | $7.17 | 945.33K |
| Oct 20, 2026 | $7.15 | $7.58 | $7.06 | $7.40 | 1.32M |
| Oct 19, 2026 | $6.98 | $7.265 | $6.95 | $7.15 | 1.3M |
| Oct 16, 2026 | $7.14 | $7.18 | $6.875 | $6.925 | 1.21M |
| Oct 15, 2026 | $6.88 | $7.28 | $6.83 | $7.16 | 1.23M |
Latest RGNX news
The latest Smart Investors Daily articles mentioning RGNX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RGNX research
Overview
Company profile and research snapshot.
Company profile
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.14
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Mizuho | Outperform | — |
| Aug 25, 2026 | Baird | Outperform | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 7, 2026
Regenxbio Inc (RGNX) (Q3 2026) Earnings Call Highlights: Dual Gene Therapy Catalysts Near ...
Regenxbio Inc (RGNX) eyes pivotal sura-vec data this quarter and a Q1 2027 BLA filing for RGX-202, backed by $251 million in cash and runway into late 2027.
Yahoo · Nov 6, 2026
REGENXBIO Q3 Earnings Call Highlights
REGENXBIO (NASDAQ:RGNX) is approaching pivotal trial results for its eye disease gene therapy and preparing a U.S. application for its Duchenne muscular dystrophy treatment, executives said during the company’s third-quarter earnings call. The company and partner AbbVie expect top-line results this
SeekingAlpha · Nov 6, 2026
Regenxbio: 2 Major Catalysts Could Change The Investment Case
Regenxbio is rated Buy, offering catalysts from ATMOSPHERE, ASCENT, and RGX-202 milestones. Click for this post-earnings RGNX update.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
